Acumen Pharmaceuticals (NASDAQ:ABOS) and Moleculin Biotech (NASDAQ:MBRX) Critical Analysis

Acumen Pharmaceuticals (NASDAQ:ABOS) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Risk and Volatility

Acumen Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.

Valuation and Earnings

This table compares Acumen Pharmaceuticals and Moleculin Biotech”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33 million	($1.86)	-1.23
Moleculin Biotech	N/A	N/A	-$33.56 million	($17.98)	-0.14

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than Moleculin Biotech, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.5% of Moleculin Biotech shares are owned by institutional investors. 10.2% of Acumen Pharmaceuticals shares are owned by company insiders. Comparatively, 1.1% of Moleculin Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Acumen Pharmaceuticals and Moleculin Biotech, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1	0	3	0	2.50
Moleculin Biotech	1	0	2	0	2.33

Acumen Pharmaceuticals presently has a consensus target price of $6.67, indicating a potential upside of 191.12%. Moleculin Biotech has a consensus target price of $22.00, indicating a potential upside of 776.49%. Given Moleculin Biotech’s higher probable upside, analysts plainly believe Moleculin Biotech is more favorable than Acumen Pharmaceuticals.

Profitability

This table compares Acumen Pharmaceuticals and Moleculin Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Moleculin Biotech	N/A	N/A	-70.93%

Summary

Moleculin Biotech beats Acumen Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.

About Moleculin Biotech

Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.